News Daily News Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe Michael O'Riordan September 20, 2016
News Daily News TAVR as an Option for Intermediate-Risk Patients: Physicians Respond Yael L. Maxwell August 24, 2016
News Daily News FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients Yael L. Maxwell August 18, 2016
News Daily News Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients Todd Neale August 01, 2016
News Daily News FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin Michael O'Riordan June 30, 2016